ORMP ORAMED PHARMACEUTICALS INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1176309 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY435.3%
TTM EPS YoY412.5%
Revenue 3-yr CAGR-11.9%
Net income 3-yr CAGR—
Margins
Gross margin0.7%
Operating margin-754.4%
Net margin3,202.5%
FCF margin-457.7%
EBITDA margin-748.4%
Returns
ROE37.0%
ROA33.2%
ROIC (approx.)-10.4%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets13.5%
Debt / equity0.00x
Current ratio6.98x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.14x
Accruals ratio37.9%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.00M | — |
| Cost of revenue | $1.99M | — |
| Gross profit | $13,000 | — |
| R&D expense | $6.38M | $6.32M |
| SG&A expense | $8.72M | $6.46M |
| Operating income | -$15.09M | -$12.78M |
| Interest expense | — | $853,000 |
| Pretax income | $75.32M | -$15.92M |
| Income tax | $11.31M | $3.18M |
| Net income | $64.05M | -$19.06M |
| EBITDA | -$14.97M | -$12.59M |
| EPS (basic) | 1.53 | -0.48 |
| EPS (diluted) | 1.50 | -0.48 |
| Dividends declared per share | 0.25 | — |
| Weighted avg. shares (diluted) | 42.42M | 40.85M |
| Balance sheet | ||
| Cash & equivalents | $45.95M | $54.42M |
| Short-term investments | $5.42M | $3.44M |
| Current assets | $133.27M | $143.22M |
| PP&E, net | $586,000 | $698,000 |
| Total assets | $230.86M | $155.28M |
| Current liabilities | $19.09M | $5.68M |
| Total liabilities | $31.12M | $9.93M |
| Shareholders' equity | $199.74M | $146.26M |
| Shares outstanding | 39.28M | 39.92M |
| Cash flow statement | ||
| Operating cash flow | -$9.14M | -$8.41M |
| Capital expenditure | $9,000 | $18,000 |
| Free cash flow | -$9.15M | -$8.43M |
| Investing cash flow | $5.44M | $105.82M |
| Financing cash flow | -$4.74M | -$52.04M |
| Depreciation & amortization | $121,000 | $193,000 |
| Stock-based compensation | $5.99M | $4.05M |
| Share buybacks | $4.74M | $2.48M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.